New research presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD), held online this year, shows that having a greater exercise capacity is associated with a significantly decreased all-cause mortality risk of between 25-33% in people with type 2 diabetes (T2D). The study was conducted by Dr Yun-Ju…
Lugano, Switzerland, 20 September 2020 – Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020. (1) “This is the first time in more…
Lugano, Switzerland, 20 September 2020 – Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant chemotherapy shows no statistically significant difference in 3-year disease-free survival (DFS), according to data presented at ESMO 2020. These results give the oncology community a long-awaited answer. (1) PORT in completely…
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice. Final results from the trial showed that olaparib – a pioneering type of drug called…